Skip To Main Content
Kefeng Ding on Muck Rack

Kefeng Ding

As seen in: Nature, Science Magazine, Cell Metabolism, Cell Press, Canadian Journal of Infectious Diseases & Medical Microbiology, EJSO - European Journal of Surgical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Kefeng Ding’s profile

Articles by Kefeng Ding

A lipoprotein-biomimetic nanoplatform for oncogenic KRAS mutation-specific lysosome-targeting protein degradation

|
By Hang Yang, Xinyi Zhou, Jiafeng Wang, Chenyue Yang, Xufeng Liao, Xiangrui Liu, Chuansheng Guo, Qian Xiao, Quan Zhou, Kefeng Ding, Yuzhao Jin
| Nature Verified
Abstract Lysosome-targeting protein degradation strategies have evolved to leverage lineage–specific receptors to improve selectivity, yet remain unable to distinguish malignant from normal cells within the same lineage.
Open in Who Shared Issue with article?

First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial

|
By Yue Liu, Yanqiao Zhang, Rongbo Lin, Xiaobing Chen, Junye Wang, Mudan Yang, Xiujuan Qu, Yunfeng Li, JiaYi Li, Weisheng Zhang, Yong Mao, Ziwei Wang, Zhenyang Liu, Jian Lei, Ye Xu, Yi Jiang, Zhanyu Pan, Liangjun Zhu, Chengcheng Liu, Min Song, Ying Yuan, Kefeng Ding
| Nature Verified
Abstract Bevacizumab plus chemotherapy is the standard first-line therapy for metastatic colorectal cancer (mCRC). To date, no phase 3 trial has compared first-line oral multitargeted TKI versus bevacizumab plus chemotherapy in RAS/BRAF wild-type mCRC. The open-label, noninferiority, randomized, phase 3 trial (ANCHOR; NCT04854668; CTR20210940) evaluated first-line anlotinib versus bevacizumab plus oxaliplatin and capecitabine (CapeOX) in this setting.
Open in Who Shared Issue with article?

Dynamic regulation of lysine and arginine metabolism promotes immune evasion by limiting T cell function in cancer

|
By WeiWei Yu, Mark Leick, Maria Pia Holgado, Ruya Sun, Xiaoyang Lu, Qiqi Deng, Heng Zhang, Sheng Chen, Siqi Dai, TianYi Hu, Xiangyuan Li, Yidong Yang, Lihao Chen, Zhexu Chi, Jian Zhang, Siwen Zhang, Yiyi Zhu, Dehang Yang, Qianzhou Yu, Zhen Wang, Quanquan Wang, Fan Yang, Qian Xiao, Kefeng Ding, Di Wang
| Science Magazine Verified
Editor’s summary Abstract Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations Check Access References Figures Tables Media Share Editor’s summary Metabolic adaptations alter the tumor microenvironment, but the impact on tumor progression and antitumor immunity remains unclear. Yu et al. revealed that lysine and arginine metabolism were dynamically altered with tumor progression across mouse tumor models and patient datasets.
Open in Who Shared Issue with article?

Bridging hydrogen-bond-stabilized polymeric coacervate core micelles for high-efficiency drug encapsulation and delivery

|
By Jiafeng Wang, Jiajia Ying, Jianxiang Huang, Longchen Zhu, Hang Yang, Junjun Li, Zimeng Liu, Yongli Mu, Changhuo Xu, Kefeng Ding, Xin Zhang, Tianhua Zhou, Xiangrui Liu, Youqing Shen, Quan Zhou
| Nature Verified
Abstract Polymeric nanoparticles represent one of the most promising classes of non-lipid-based drug delivery vehicles. However, their clinical translation remains limited by poor drug loading capacity and suboptimal delivery efficiency. We here develop one type of polymeric nanoparticles, referred to as PCCMs (Polymeric Coacervate Core Micelles), which are assembled from a sulfoxide-containing block polymer.
Open in Who Shared Issue with article?

16-h fasting optimizes cancer immunotherapy in mice and humans

|
By Sheng Chen, TianYi Hu, Kaixiang Zhu, Yue Liu, Yidong Yang, Xiangyuan Li, Jinjie He, Wenyu Cui, Zhexu Chi, WeiWei Yu, Duojiao Chen, Zhen Wang, Jian Zhang, Ruya Sun, Dehang Yang, Siqi Dai, Qianzhou Yu, Quanquan Wang, Qian Xiao, Junbin Qian, Kefeng Ding, Di Wang
| Cell Metabolism Verified
Keywords diet intervention immune checkpoint therapy immunometabolism tumor metabolism tumor microenvironment Introduction The tumor microenvironment (TME) is a metabolically competitive niche where malignant cells outcompete immune cells for limited nutrients, including carbohydrates, amino acids, and lipids.1,2 During cancer progression, tumor cells exploit metabolic plasticity to upregulate diverse metabolic pathways, such as glycolysis, glutaminolysis, and lipid metabolism.3,4,5 However,...
Open in Who Shared Issue with article?

Stepwise transcription stalling by the anti-cancer drug Actinomycin D and insights into short tandem repeat transcription inhibition

|
By Weiqi Zhao, Yankai Liu, Wenjing Deng, Xu Yang, Zhiyuan Jerry Lin, Kefeng Ding, Xin Yang, Xuekun Li, Jun Xu, Liulian Zhu
| Nature Verified
Abstract Short tandem repeats (STRs) comprise 6% of the human genome, and their transcription is linked to over 60 diseases. Actinomycin D (ACTD) is the first clinically approved anticancer antibiotic that inhibits transcription through an incompletely understood mechanism. Here, using reconstituted yeast and mammalian systems, we investigate the mechanism of transcription inhibition and examine the impact of ACTD on STR transcription.
Open in Who Shared Issue with article?

Hepatic micropeptide modulates mitochondrial RNA processing machinery in hepatocellular carcinoma

|
By Linyu Zhu, Fangzhou Liu, Chengyu Shi, Xinwan Su, Manman Tan, Shaofang Xie, Meng Yu, Sailan Zou, Yinuo Tan, Shanshan Xie, Jian Liu, Qingfeng Yan, Dante Neculai, Qiming Sun, Wei Liu, Yuan Ding, Xianghui Fu, Jianzhong Shao, Xu Li, Kefeng Ding, Ying Yuan, Tianhua Zhou, Aifu Lin
| Cell Press Verified
1Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China 2MOE Laboratory of Biosystem Homeostasis and Protection, College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang 310000, China 3Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310000, China 4Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School...
Open in Who Shared Issue with article?
Show More